Skip to main content

Advertisement

Contact Yuankai Shi

From: Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

Contact corresponding author